
Keywords: آنتی ژن های مرتبط با تومور; HCC; cancer vaccine; HEPAVAC; HLA-ligandome; HCC; hepatocellular carcinoma; ASR; age-standardized rate; HBV; hepatitis B virus; HCV; hepatitisC virus; TAAs; Tumor-associated antigens; DAMPs; damage-associated molecular patterns; DCs; dendritic cells; AFP;